All eyes are on Jubilant Pharmova after a management meeting wherein the top brass seemed confident of posting double-digit growth across most businesses. Nirmal Bang caught up with the management to get an overview of the current business environment and growth opportunities in the company’s different business verticals. Radiopharma business is back to pre-covid level and is expected to grow in double digits from FY24 on the back of new launches and ramp-up in Ruby-fill. The allergy business continues to witness double-digit growth with healthy margins. In the CDMO Sterile Injectables business, they are expecting double-digit growth from FY24 onwards. For detailed takeaways from the management meeting, listen in.#ETNow #JubilantPharmova #LatestNews